Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

Cooperative Study Group A for Hematology

Status and phase: Unknown; Phase 2

Conditions: Lymphoma

Treatments: Drug: GemDOx

Study type: Interventional

Funder types: NETWORK

Identifiers

NCT00561301

C-012A

Details and patient eligibility

About

• To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)

Full description

• The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.

Enrollment: 43 estimated patients

Sex: All

Ages: 15 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have refractory to first-line CHOP-like regimen
• Patients who have first relapse after
• first-line CHOP-like regimen
• upfront autologous or allogeneic hematopoietic stem cell transplantation
• Age 15 years or more
• ECOG performance status ≤ 2
• Adequate bone marrow function
• Adequate kidney,liver,cardiac

Exclusion criteria

• Patients who have received GEM or OX

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

43 participants in 1 patient group

1

No Intervention group

Treatment:

Drug: GemDOx